Integra LifeSciences Holdings (IART)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 246,375 | 276,402 | 456,661 | 513,448 | 470,166 |
| Short-term investments | US$ in thousands | 27,192 | 32,694 | 0 | — | — |
| Total current liabilities | US$ in thousands | 922,126 | 306,980 | 320,906 | 340,021 | 401,013 |
| Cash ratio | 0.30 | 1.01 | 1.42 | 1.51 | 1.17 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($246,375K
+ $27,192K)
÷ $922,126K
= 0.30
The cash ratio for Integra LifeSciences Holdings has fluctuated over the past five years. Starting at 1.17 on December 31, 2020, it increased to 1.51 by December 31, 2021, indicating the company had $1.51 in cash and cash equivalents for every $1 of current liabilities. Subsequently, the ratio decreased to 1.42 by December 31, 2022, before dropping to 1.01 by December 31, 2023.
The most significant change occurred by December 31, 2024, when the cash ratio drastically declined to 0.30. This decrease may signal a potential liquidity concern, as the company now holds only $0.30 in cash and cash equivalents for every $1 of current liabilities. It's essential for Integra LifeSciences Holdings to closely monitor its cash position and manage its liquidity effectively to ensure it can meet its short-term obligations.
Peer comparison
Dec 31, 2024